LILLY ZYPREXA RELAPSE PREVENTION CLAIM BEING DISCUSSED WITH FDA FOR PHASE IV; OLANZAPINE PARKINSON-LIKE SIDE EFFECTS ARE SIMILAR TO PLACEBO EXPERIENCE
Executive Summary
Lilly is pursuing an explicit maintenance claim for the anti-psychotic Zyprexa in Phase IV discussions with FDA following the approval of the drug. The company and FDA will confer on the definition and endpoints that would be required to demonstrate relapse prevention in schizophrenic populations that could lead to a maintenance indication for Zyprexa. There is a lack of consensus in the U.S. scientific community on how to define relapse prevention, Lilly says.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth